Building the Ideal Bioprocessing Strategy
Searching for Innovative, Cost-Effective Product Options
When Success Rates Go Low, Cell-Based Screens Go High
To Boost Success Rates, Developers are Balancing High-Content and High-Throughput Screening
Top 10 European Biopharma Clusters
As Brexit Casts Uncertain Shadow, Continent’s Industry Continues Growth Trajectory
Non-Viral, Plasmid-Free CAR T-Manufacturing Platform Begins Preclinicals
Goal Is the Development of Faster, More Affordable Therapies
For full access to this article login to GEN Select now.
Supplement: The Expanding CRISPR-Cas Toolbox
If Your Only CRISPR Nuclease Is Cas9, Your Options May Be Limited
- Microbes are great teachers, and they never disappoint. Among the most recent things that we learned from bacteria and archaea is that they possess many defenses against environmental attacks such as those initiated by viruses. Bacteria, for example, make good use of an adaptive immune system called CRISPR -Cas. ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.